Dual/Tandem CAR Development Service for Solid Tumor Targeting

Creative Biolabs offers a cutting-edge Dual/Tandem CAR Development Service for Solid Tumor Targeting, designed to overcome the challenges of antigen escape and low response rates in immuno-oncology. By integrating advanced multi-antigen recognition and context-optimized CAR engineering, this platform enhances tumor specificity and reduces relapse risk. Our comprehensive approach empowers researchers to develop potent, next-generation CAR-T therapies capable of effectively combating the immunosuppressive tumor microenvironment and improving clinical outcomes in solid tumor treatment.

Introduction

CAR-T therapy's success in blood cancers has not extended to solid tumors due to nonspecific targeting and the hostile tumor microenvironment. Scientific reviews confirm that overcoming these hurdles requires next-generation engineering strategies, including multi-targeting and combination therapies. Studies of Dual CARs show significantly improved complete remission rates by preventing antigen escape, demonstrating this approach's critical role in developing curative solid tumor therapies.

Fig.1 Challenges of CAR T-cell immunotherapy in solid tumors.^1,3

Service

We provide a comprehensive strategy to move beyond the limitations of single-target CAR-T therapy, which often fails due to the heterogeneity of solid tumors. Our service focuses on engineering CAR T cells that simultaneously recognize two different tumor-associated antigens (TAAs) or target two distinct cell populations within the tumor microenvironment (TME).

• Mitigate Antigen Escape: By targeting two distinct antigens, we drastically reduce the probability of tumor cells evading immune recognition through the loss or downregulation of a single target.
• Increase Therapeutic Window: The requirement for dual antigen recognition enhances the specificity of T-cell activation, improving the targeting of malignant cells while minimizing the risk of on-target, off-tumor toxicity against healthy tissues expressing only one of the targets at a low level.
• TME-Optimized Construct Design: We leverage advanced design principles, including the selection of the most effective co-stimulatory domains, to ensure superior T-cell persistence, reduced exhaustion, and robust proliferation against the specific solid tumor target.

Discover How We Can Help - Request a Consultation.

What We Can Offer

Our service integrates the most advanced molecular and cellular platforms to ensure the highest quality and efficacy of your dual-targeting CAR-T candidates. We offer a flexible and modular system to develop and evaluate your custom construct.

Our Workflow

The Dual/Tandem CAR-T development process starts with target validation and design of optimal scFvs and co-stimulatory domains, followed by CAR sequence optimization. The construct is cloned into viral vectors and produced at high titer. T cells are isolated, activated, transduced, and expanded. Functional in vitro assays confirm specificity, cytotoxicity, and persistence. Optionally, the final CAR-T product is formulated for pre-clinical studies, fully characterized, and provided with an analysis for immediate research use.

Advantages

• Context-Specific Co-Stimulatory Domain (CSD) Expertise: We do not rely on a single, default CSD. Our proprietary library allows us to select CSDs proven to be superior for specific target / tumor combinations, ensuring maximum anti-tumor activity and reduced T-cell exhaustion.
• Validated Dual-Targeting Platforms: We have a proven track record of successfully engineering multi-antigen-targeting systems, providing the technical confidence needed to tackle antigen heterogeneity, a primary cause of solid tumor relapse.
• Ready Manufacturing Experience: Our processes and documentation are designed with future regulatory submission in mind, ensuring a seamless transition from preclinical success to clinical manufacturing.

Data Support

This research developed CAR-T therapies targeting CD276 and FGFR4 to treat a childhood muscle cancer. CD276-targeted therapy showed strong efficacy, especially against high-CD276 tumors, often achieving complete remission in mice. While FGFR4-targeting was more specific, it was less potent. A combined Dual-CAR approach demonstrated high effectiveness.

Fig.2 Tumor clearance experiment with dual CAR T-cells in an orthotopic mouse model.^2,3

FAQs

Partner with Us

Creative Biolabs is your expert partner in tackling the complexities of solid tumor immunotherapy. Our Dual/Tandem CAR Development Service leverages proprietary engineering and data-driven design to ensure your next-generation CAR-T candidates possess the enhanced specificity and functional persistence required for clinical success.

Customer Reviews

"The team's CD28-based design was a game-changer, producing T cells with superior expansion, reduced exhaustion, and a strong central memory phenotype compared to our 4-1BB construct, accelerating in vivo testing." - J**n L., Principal Scientist.

"The rigorous in vitro validation against multiple cell lines provided high confidence in our construct's on-target specificity, significantly de-risking our submission package." - C**y T., Medicine Lead.

For detailed project assessment, technical discussions, and custom quote generation, please reach out to our specialist team.

References

1. Zhu, Jiajun et al. "Advancements and challenges in CAR-T cell therapy for solid tumors: A comprehensive review of antigen targets, strategies, and future directions." Cancer Cell International vol. 25,1 313. 23 Aug. 2025. https://doi.org/10.1186/s12935-025-03938-0
2. Zhang, Bohan et al. "Strategies to Overcome Antigen Heterogeneity in CAR-T Cell Therapy." Cells vol. 14,5 320. 20 Feb. 2025. https://doi.org/10.3390/cells14050320
3. Distributed under Open Access License CC BY 4.0, without modification.